What Johnson & Johnson’s AKEEGA opinion means for PARP inhibitors beyond castration resistance
Find out how Johnson & Johnson’s CHMP opinion for AKEEGA could shift prostate cancer treatment toward earlier, biomarker-guided precision therapy.
Can Idorsia Pharmaceuticals Ltd’s lucerastat redefine Fabry disease treatment beyond enzyme replacement therapy?
Discover how Idorsia Pharmaceuticals Ltd’s FDA-aligned Phase 3 plan could make lucerastat the first oral therapy for all Fabry disease patients. Read the analysis.
Why Pulmovant’s PHocus study design matters for regulatory confidence in pulmonary hypertension associated with interstitial lung disease
Pulmovant completes PHocus enrollment for mosliciguat in PH-ILD. Find out what this milestone really means ahead of 2026 clinical data.
How Priovant’s brepocitinib advances a long-overlooked inflammatory skin disease toward approval
Strong Phase 2 data put brepocitinib on a rare pivotal path in cutaneous sarcoidosis. Find out what this changes for clinicians and regulators.
Can Ampligen plus durvalumab finally overcome immunotherapy resistance in metastatic pancreatic cancer
Explore what AIM ImmunoTech’s Ampligen Phase 2 data could change for pancreatic cancer immunotherapy and what risks still remain.
What Propanc Biopharma’s PRP signals about alternative mechanisms in the crowded pancreatic cancer pipeline
Can PRP’s proenzyme approach change pancreatic cancer treatment strategy? Explore what Propanc Biopharma’s data means for oncology innovation.
BioSelective Capital’s CDMO acquisition reshapes domestic pharma manufacturing landscape
Forma Life Sciences launches from BioDuro’s CDMO assets. See how this reshoring move changes U.S. oral formulation outsourcing and CDMO competition in 2026.
Why Brightseed’s glycemic control data could reshape how GLP-1 companion products are evaluated
Peer-reviewed data puts Brightseed’s BioMetaControl under the clinical microscope. Find out what this trial means for GLP-1 companions and metabolic care.
How Leyden’s CR9114 nasal spray could disrupt traditional flu vaccination models
Could a nasal spray replace flu shots? Find out how Leyden Labs’ CR9114 antibody is changing the game in influenza prevention.
Is JCR unlocking the CNS for lysosomal storage diseases before gene therapy gets there?
Find out how JCR Pharmaceuticals is redefining lysosomal disease therapy with brain-targeted delivery platforms.